Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Chardan Serves as Lead Manager for LogicBio Therapeutics
By: PR Newswire Association LLC. - 22 Oct 2018Back to overview list

NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as lead manager in the initial public offering of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), raising aggregate gross proceeds of approximately $70.0 million. LogicBio began trading on the NASDAQ Capital Market on October 19, 2018.

Chardan has participated in advisory and capital raising transactions totaling more than $2 billion in 2018.

About Chardan

Chardan is an independent global investment bank specializing in healthcare, SPACs and emerging growth companies. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc.

Learn more about Chardan: www.chardan.com

Media Contact:
Emily Levine, Chardan
elevine@chardan.com 
(646) 465-9018

Tom Rozycki, Prosek Partners
trozycki@prosek.com 
(646) 503-5657

Cision View original content:http://www.prnewswire.com/news-releases/chardan-serves-as-lead-manager-for-logicbio-therapeutics-300735489.html

SOURCE Chardan Capital Markets, LLC

Related companies:LogicBio Therapeutics Inc. | Chardan Capital Markets, LLC
Copyright 2018 PR Newswire Association LLC. Back to overview list
to the top ↑